

DSIR
AWARDS

THE ECONOMIC TIMES MUMBAI
* FRIDAY 10 OCTOBER 1997

CHECKLIST

Themis Chemicals wins dept of science award

THEMIS Chemicals (Artemis) has won an award from the ministry of science and technology's department of scientific and industrial research (DSIR) for outstanding achievements in R & D.

The company has won the award for developing and commercialising technology for Lovastatin, a cholesterol reducing agent, through biotechnology. Themis has installed a plant for the manufacture of the product, and has filed for two non-infringing process patents in India.

DSIR award for pharmaceutical company

EXPRESS NEWS SERVICE
AHMEDABAD, OCT 6

THEMIS Chemicals Limited has received the DSIR National Award for R&D Efforts in the Industry for its outstanding contribution in the field of biotechnology.

A Themis Chemicals Press note stated that the award has been instituted by the Department of Scientific and Industrial Research (DSIR), a wing of the Ministry of Science and Technology, Government of India, for outstanding research and development achievement of national importance.

The note further stated that the company is the first in Asia and third in the world to develop the technology for the bulk drug Lovastatin, a cholesterol reducing agent.

Lovastatin provides a new lease of life for patients suffering from high cholesterol by bringing down the cholesterol level, thus reducing the incidence of heart attacks.

AHMEDABAD Newsline
TUESDAY 07 OCTOBER 7, 1997

Themis bags DSIR award

Themis Chemicals, the Mumbai-based pharmaceutical company, has received the "DSIR National Award for R&D in Industry" for developing Lovastatin, a cholesterol reducing agent. The company is the first in Asia and third in the world to develop an indigenous technology for making the product and commercialising it. Two non-infringing process patents have been filed by Themis in India. With the indigenous production of the drug in the country, the cost per tablet will come down from Rs 24 - Rs 12. Themis has a capacity of three tonnes per annum (tpa) and will be doubled in the next two years, a company release said.

BUSINESS STANDARD MUMBAI TUESDAY OCTOBER 7 1997


The **Financial** Express

MUMBAI • SATURDAY, OCTOBER 4, 1997

Themis Chemicals bags DSIR award: Themis Chemicals Ltd and group company Artemis have received the department of science and industrial research (DSIR) award for its outstanding contribution in the field of biotechnology. The DSIR is part of the ministry of

science and technology. The product in question is Lovastatin, a cholesterol-reducing agent. With the indigenous production of Lovastatin, formulators in India can offer their tablets at Rs 10 to Rs 12 per tablet compared with Rs 24 per tablet, when the drug was being imported.

MR. DUTTA



Themis Chemicals wins award for R & D

AHMEDABAD: Themis Chemicals Limited has been awarded the prestigious DSIR National Award for R & D efforts in the industry for its contribution to biotechnology, says a release. The award is instituted by the department of scientific and industrial research, a wing of the ministry of science and technology for outstanding R & D achievement. The company says it is the first in Asia and third in the world to develop the technology for the bulk drug 'Lovastatin,' a cholesterol reducing agent.

THE TIMES OF INDIA, AHMEDABAD

FRIDAY, OCTOBER 10, 1997

Themis Chem bags national R&D award

Our Ahmedabad Bureau

10 OCTOBER

THEMIS Chemicals Ltd (TCL) has been awarded the prestigious 'DSIR National Award for R&D efforts in the industry' for its outstanding contribution to the field of biotechnology.

The award had been instituted by the department of scientific and industrial research (DSIR), a wing of the ministry of science and technology, Government of India, for outstanding R&D achievement of national value.

In a press release, the company claimed to have been the first in Asia and third in the world to develop the technology for the bulk drug—Lovastatin, a cholesterol reducing agent.

Lovastatin provides a new lease of life for patients suffering from high cholesterol. By reducing cholesterol levels, it reduces the incidence of heart attacks.

The indigenous production of Lovastatin has made it possible for formulators in India to substantially reduce the price of their drugs.

THE ECONOMIC TIMES
AHMEDABAD SATURDAY 11 OCTOBER 1997

CORPORATE NOTES

Themis Chem (Artemis) wins DSIR award

Themis Chemicals (Artemis) has won an award from the ministry of science and technology's department of scientific and industrial research (DSIR) for outstanding achievements in R & D. The company has won the award for developing and commercialising technology for Lovastatin, a cholesterol reducing agent, through biotechnology. Themis has installed a plant for the manufacture of the product, and has filed for two non-infringing process patents in India.

GM expands dealer network

General Motors has expanded its dealer network in Mumbai with the opening of a new dealership at Vashi, New Mumbai. The dealership, Manaki Automobiles, was opened to cater to the growing Opel Astra customer base in New Mumbai. Manaki Automobiles becomes GM's fourth dealership in Mumbai with the earlier three dealerships being National Garage, Shiraz Motors and Manaki Automobiles at Thane.

HK govt gives accreditation to UPS firm from Pune

The government Supplies Department, Hong Kong, has registered Enertech Electronics as a government supplier for uninterruptible power supply systems. Enertech Electronics is the only UPS manufacturer from India to be given this status for a standby power management product by the Hong Kong government.

CORPORATE BRIEFING

Themis Chemicals bags award: Themis Chemicals Ltd of Vapi in south Gujarat, the first in Asia and third in the world to develop the bulk drug technology for 'Lovastatin', has been awarded the prestigious DSIR National Award for its contribution to biotechnology. The award was instituted by Department of Scientific and Industrial Research (DSIR) for outstanding research and development achievement of national value.

The Financial Express

MUMBAI • MONDAY, OCTOBER 13, 1997